Veda Prachayasittikul

Dr. Veda Prachayasittikul


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
VPVeda Prachayasittikul
Veda Prachayasittikul
SPSupaluk Prachayasittikul
Supaluk Prachayasittikul
SRSomsak Ruchirawat
Somsak Ruchirawat
VPVirapong Prachayasittikul
Virapong Prachayasittikul
Peer reviewed article authored by (Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V). Read article or submit your manuscript for publishing.

1 March 2018 in Food Research International
Verified
Journal Article
Closed access
VPVeda Prachayasittikul
Veda Prachayasittikul
SPSupaluk Prachayasittikul
Supaluk Prachayasittikul
SRSomsak Ruchirawat
Somsak Ruchirawat
VPVirapong Prachayasittikul
Virapong Prachayasittikul

16 June 2015 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VPVeda Prachayasittikul
Veda Prachayasittikul
AWApilak Worachartcheewan
Apilak Worachartcheewan
Watshara ShoombuatongWatshara Shoombuatong
Watshara Shoombuatong
NSNapat Songtawee
Napat Songtawee
SSSaw Simeon
Saw Simeon
CNChanin Nantasenamat
Chanin Nantasenamat
Natural products have been an integral part of sustaining civilizations because of their medicinal properties. Past discoveries of bioactive natural products have relied on serendipity, and these compounds serve as inspiration for the generation of analogs with desired physicochemical properties. Bioactive natural products with therapeutic potential are abundantly available in nature and some of them are beyond exploration by conventional methods. The effectiveness of computational approaches as versatile tools for facilitating drug discovery and development has been recognized for decades, without exception, in the case of natural products. In the post-genomic era, scientists are bombarded with data produced by advanced technologies. Thus, rendering these data into knowledge that is interpretable and meaningful becomes an essential issue. In this regard, computational approaches utilize the existing data to generate knowledge that provides valuable understanding for addressing current problems and guiding the further research and development of new natural-derived drugs. Furthermore, several medicinal plants have been continuously used in many traditional medicine systems since antiquity throughout the world, and their mechanisms have not yet been elucidated. Therefore, the utilization of computational approaches and advanced synthetic techniques would yield great benefit to improving the world’s health population and well-being.

1 July 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RPRatchanok Pingaew
Ratchanok Pingaew
VPVeda Prachayasittikul
Veda Prachayasittikul
PMPrasit Mandi
Prasit Mandi
CNChanin Nantasenamat
Chanin Nantasenamat
SPSupaluk Prachayasittikul
Supaluk Prachayasittikul
VPVirapong Prachayasittikul
Virapong Prachayasittikul

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RPRatchanok Pingaew
Ratchanok Pingaew
PMPrasit Mandi
Prasit Mandi
VPVeda Prachayasittikul
Veda Prachayasittikul
SPSupaluk Prachayasittikul
Supaluk Prachayasittikul
SRSomsak Ruchirawat
Somsak Ruchirawat
VPVirapong Prachayasittikul
Virapong Prachayasittikul

18 May 2022 in ACS Omega
Verified
Journal Article
Open access
PMPanupong Mahalapbutr
Panupong Mahalapbutr
RLRonnakorn Leechaisit
Ronnakorn Leechaisit
ATAnusit Thongnum
Anusit Thongnum
DTDuangjai Todsaporn
Duangjai Todsaporn
VPVeda Prachayasittikul
Veda Prachayasittikul
APA. Pingaew
A. Pingaew
Epidermal growth factor receptor (EGFR) has been recognized as one of the attractive targets for anticancer drug development. Herein, a set of anilino-1,4-naphthoquinone derivatives (3-18) was synthesized and investigated for their anticancer and EGFR inhibitory potentials. Among all tested compounds, three derivatives (3, 8, and 10) were selected for studying EGFR inhibitory activity (in vitro and in silico) due to their most potent cytotoxic activities against six tested cancer cell lines (i.e., HuCCA-1, HepG2, A549, MOLT-3, MDA-MB-231, and T47D; IC50 values = 1.75-27.91 μM), high selectivity index (>20), and good predicted drug-like properties. The experimental results showed that these three promising compounds are potent EGFR inhibitors with nanomolar IC50 values (3.96-18.64 nM). Interestingly, the most potent compound 3 bearing 4-methyl substituent on the phenyl ring displayed 4-fold higher potency than the known EGFR inhibitor, erlotinib. Molecular docking, molecular dynamics simulation, and MM/GBSA-based free energy calculation revealed that van der Waals force played a major role in the accommodations of compound 3 within the ATP-binding pocket of EGFR. Additionally, the 4-CH3 moiety of the compound was noted to be a key chemical feature contributing to the highly potent EGFR inhibitory activity via its formations of alkyl interactions with A743, K745, M766, and L788 residues as well as additional interactions with M766 and T790.